Avantium appoints bioplastics specialist
Jeffrey Kolstad joins as chief scientist from NatureWorks
Previously chief scientist at NatureWorks (formerly Cargill-Dow), Kolstad was one of the founding members of the team that developed and commercialised PLA (polylactic-acid), a bio-based polymer. He was also responsible for managing NatureWorks’ IP portfolio and strategy.
Prior to this Kolstad worked in the corporate research centres at Cargill and Amoco Oil Company.
You may also like
Sustainability
BioDuro sites recognised with EcoVadis Gold and Silver sustainability certifications
Three of the CDMO's Chinese sites have been recognised for outstanding sustainability performance, highlighting BioDuro’s commitment to sustainability and its ongoing efforts to embed environmental and social responsibility into its business operations
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform